<ul><li>The US Commerce Department has launched a Section 232 investigation into pharmaceutical imports, raising concerns over the future of India’s $10 billion drug exports.</li><li>The probe will assess the extent to which India's reliance on foreign pharmaceutical imports could pose a threat to the US domestic healthcare system.</li><li>India is among the top five pharmaceutical suppliers to the US, but European suppliers have retained or expanded their shares.</li><li>The investigation under Section 232 of the US Trade Expansion Act marks a shift in US trade policy towards the pharmaceutical sector.</li></ul>

India’s $10 Billion Pharma Exports To US Face Probe Risk As Trade Tensions Rise

Discover more